Clinical Features, Outcomes, and Therapeutics of Pregnancy-Related Aortic Dissection

Pregnancy Related Clinical Trial

Official title:

Clinical Features, Outcomes, and Therapeutics of Ppregnancy-related Aortic Dissection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05501145
• Other study ID #: 5A Plan VII
• Status: Completed
• Start date: January 1, 2022
• Est. completion date: July 31, 2022

Study information

• Verified date: September 2022
• Source: Nanjing Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Aortic dissection in pregnancy represents a lethal risk to both the mother and fetus, it has yet to yield the optimal therapeutic strategy. The aim of this study was to characterize the clinical features and outcomes in women with pregnancy-related acute aortic dissection, and to suggest therapeutic guidelines.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: July 31, 2022
• Est. primary completion date: July 31, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Women who presented with aortic dissection during pregnancy or post partum =12 weeks.

Exclusion Criteria:

• Loss of surgical information.

Related Conditions & MeSH terms

• Aneurysm, Dissecting
• Aortic Dissection
• Pregnancy Related

Intervention

Procedure:
• cesarean section and aortic repair
The timing of aortic repair and delivery have to be determined based on the type of the dissection, the stage of pregnancy (the gestation age), and the status of the fetus, as well as the level of local neonatal service.

Locations

Country	Name	City	State
China	Beijing Anzhen Hospital	Beijing
China	Department of Obstetrics and Gynecology, Guangdong Provincial People's Hospital	Guangzhou
China	Department of Cardiac Surgery, Affiliated Hospital of Qingdao University	Qingdao
China	Department of Obstetrics and Gynecology, Zhongshan Hospital	Shanghai

Sponsors (4)

Lead Sponsor	Collaborator
Nanjing Medical University	Beijing Anzhen Hospital, Guangdong Provincial People's Hospital, Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	30-day mortality		30 days after surgery